Mechanism of Action: Imetelstat in LR MDS

Opinion
Video

  • Please discuss the mechanism of action for imetelstat, a first-in-class oligonucleotide telomerase inhibitor in LR-MDS.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
1 expert in this video
1 expert in this video
3 experts are featured in this series.
1 expert in this video
3 experts are featured in this series.
1 expert in this video
3 experts are featured in this series.
Related Content
IFx-Hu2.0 Enters Clinical Trials for Merkel Cell Carcinoma

IFx-Hu2.0 Enters Clinical Trials for Merkel Cell Carcinoma

Jordyn Sava
May 7th 2025
Article

Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.

Read More

Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

Nichole Tucker
June 30th 2023
Podcast

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

Listen

TCMCB07 Enters Phase 2 for Weight Loss in Stage IV Colorectal Cancer

TCMCB07 Enters Phase 2 for Weight Loss in Stage IV Colorectal Cancer

Jordyn Sava
April 22nd 2025
Article

Following promising phase 1 data, TCMCB07 is being further evaluated in a phase 2 trial for the treatment of patients with stage IV colorectal cancer.

Read More

First Patient Receives KSQ-004EX for Advanced Cancer

First Patient Receives KSQ-004EX for Advanced Cancer

Jordyn Sava
April 12th 2025
Article

A phase 1/2 trial of CRISPR-engineered eTIL therapy KSQ-004EX for advanced solid tumors has dosed its first patient.

Read More

CT-95 Phase 1 Trial Enrolls and Doses First Patient With MSLN+ Advanced Cancer

CT-95 Phase 1 Trial Enrolls and Doses First Patient With MSLN+ Advanced Cancer

Jordyn Sava
April 10th 2025
Article

A phase 1 open-label trial is underway, evaluating the safety and efficacy of CT-95 in patients with mesothelin-expressing advanced solid tumors.

Read More

Phase 1/2 Trial of TTX-MC138 Doses First Patient in Cohort 4

Phase 1/2 Trial of TTX-MC138 Doses First Patient in Cohort 4

Jordyn Sava
March 31st 2025
Article

The fourth cohort of an ongoing phase 1/2 has dosed its first patient with TTX-MC138 in advanced solid tumors.

Read More